The Dutch healthcare institute "Zorginstituut Nederland" said recently insurers should stop paying for expensive drugs if pharmaceutical companies continue to refuse to say how they arrive at their pricing.
The institute, which assesses the efficacy of new drugs and advises the government on whether they should be included in the basic healthcare policy, says the drugs companies are effectively blackmailing officials by refusing to be transparent about their prices.
Last years June announcement that Ireland is joining the Beneluxa Initiative on Pharmaceutical Policy might suggest renewed vigour for the drive to equip national governments with more clout in their pricing negotiations with international drug firms.
The likelihood is that better-informed health authorities will be better equipped to confront drug firms. Similarly, drug firms will be obliged to present more cogent justifications for their pricing ambitions/
As has been proven in the US, Pharmaceutical companies. also known there as "Big Pharma, can not be left operating with little or no strict Governmental controls.
In the US this has led to a steady rise in the cost of pharmaceutical products for consumers.
It is more than obvious the Pharmaceutical industry must be closely monitored in two major areas: a) Their pricing structures and practices, and b) Providing far more transparency in their marketing and sales activities, specifically as it relates to the insurance and medical industry.
In Europe the initiatives of the Beneluxa Initiative on Pharmaceutical Policy certainly are a step in the right direction, but unfortunately Government support and action has been extremely slow, while the Pharmaceutical lobby in the EU Parliament, however, like it has been in the US Congress and Senate, has been vigorous and very effective.
The Dutch healthcare
institute Zorginstituut Nederland said in February insurers should stop
paying for expensive drugs if pharmaceutical companies continue to
refuse to say how they arrive at the price.
The institute, which assesses the efficacy of new drugs and advises the
government on whether they should be included in the basic healthcare
policy, says the drugs companies are effectively blackmailing officials
by refusing to be transparent about their prices.
Leadiant Biosciences told DutchNews.nl in a statement: ‘We follow the
discussion and the AMC initiative. Bringing medicines for rare diseases
like CTX to patients and families in need requires a collaboration
between industry and health systems, including governments, regulators,
insurers, advocacy groups, and health professionals.
‘At the heart of the issue is ensuring the medicines we develop and
deliver meet the appropriate standards of safety, efficacy and quality –
and are accessible to the people who need them. We will continue to
engage with the relevant stakeholders on solutions that address these
needs.’
The company did not comment on the reason behind the price hike.
Read more at DutchNews.nl:
